BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Raised to "Strong-Buy" at UBS Group

Key Points

• UBS Group upgraded BioMarin Pharmaceutical to “strong buy,” joining a generally positive analyst consensus of “moderate buy.” The average analyst price target is $88.87, with several firms recently raising their targets to between $105 and $114.
• BioMarin shares fell 2.4% to $54.68, remaining below their 50-day moving average of $63.01 but above the 52-week low of $49.26. The stock has a market capitalization of approximately $10.58 billion.
• The company’s latest quarterly results exceeded expectations, with earnings of $1.20 per share versus a $0.95 estimate and revenue of $989.71 million, up 20% year over year. Institutional investors own approximately 98.71% of the stock.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) was upgraded by investment analysts at UBS Group to a "strong-buy" rating in a report issued on Wednesday, Zacks reports.

Several other research firms also recently commented on BMRN. Canaccord Genuity Group increased their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Oppenheimer boosted their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an "outperform" rating in a research report on Friday, August 7th. William Blair upgraded BioMarin Pharmaceutical to a "hold" rating in a research note on Wednesday, September 23rd. Barclays increased their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Jefferies Financial Group increased their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a "buy" rating in a report on Monday, August 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $88.87.

BioMarin Pharmaceutical Stock Down 2.4%

NASDAQ BMRN traded down $1.37 during trading on Wednesday, reaching $54.68. The company's stock had a trading volume of 2,627,811 shares, compared to its average volume of 2,366,833. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $10.58 billion, a PE ratio of 147.78, a PEG ratio of 0.39 and a beta of 0.22. The business has a 50-day moving average price of $63.01 and a 200-day moving average price of $58.66. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company's revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts forecast that BioMarin Pharmaceutical will post 4.10 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mather Group LLC. lifted its holdings in shares of BioMarin Pharmaceutical by 71.0% during the third quarter. Mather Group LLC. now owns 2,337 shares of the biotechnology company's stock worth $140,000 after buying an additional 970 shares during the last quarter. Sanders Morris Harris LLC bought a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $240,000. Wedmont Private Capital acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter worth $222,000. GAMMA Investing LLC grew its stake in shares of BioMarin Pharmaceutical by 50.4% in the third quarter. GAMMA Investing LLC now owns 3,642 shares of the biotechnology company's stock worth $219,000 after acquiring an additional 1,220 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 7.9% in the third quarter. Farther Finance Advisors LLC now owns 8,489 shares of the biotechnology company's stock worth $509,000 after acquiring an additional 618 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.